: Media


09 - 10 June 2022 | Berlin, Germany
+ Digital Day: 13 June 2022 | Online

Content HUB

Our Content HUB gives you access to complimentary resources including Webinars, Market Industry Reports, Q&A Sessions, Newsletters and much more.

Journal Collaborations & Media Partners

The Discovery Series marketing team work with leading journal publications on reciprocal marketing arrangements.

If you are interested in promoting your journal/association to the leading players in this industry please contact us.


PharmaVision offers a consultancy service providing high quality, due diligence research and independent, tailor made life science reports to pharmaceutical companies, competitive intelligence specialists, investment institutions and healthcare communication agencies. The research reports combine in-depth interviews with key opinion leaders, scientific analysis with market models to forecast the potential growth of key developmental products and technologies, identify marker drivers/resistors and identify unique selling features to guide product development

Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology News (GEN) is a flagship publication of Mary Add Liebert, Inc. Launched in 1980 GEN was the first publication in the field and remains key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth and career opportunities. GEN maintains unrivaled integrity, influence and expertise that plays a pivotal role in driving the productivity and growth of the industry.


Cardea is a next-generation biotechnology company transforming industries with handheld products that detect whole biology in minutes. Cardea’s breakthrough graphene biosensor platform harnesses hardware, software, and molecular infrastructure to detect and convert any biological signal of interest into measurable digital information without optics or amplification. The company recently launched a biology-gated transistor based on CRISPR-Chip™ technology, called The Genome Sensor™. Ask about Cardea’s Innovation Partnership Program and use our technology to Search Life™.


PharmaVOICE magazine reaches more than 46,000 BPA qualified subscribers and 60,000 users with its digital edition. PharmaVOICE is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including Social Media, WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts.


High-Throughput (ISSN 2076-3905) is an open accessed, PubMed and Scopus indexed multidisciplinary peer-reviewed scientific journal that provides an advanced forum for the publication of studies reporting high-dimensional approaches and developments in Life Sciences, Chemistry and related fields. Our aim is to encourage scientists to publish their experimental and theoretical results based on high-throughput techniques as well as computational and statistical tools for data analysis and interpretation.


Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes.


Pharmaceuticals (ISSN 1424-8247) is an open accessed, PubMed and ESCI indexed journal of medicinal chemistry and related drug sciences, published quarterly online by MDPI. Manuscripts are peer-reviewed and a first decision provided to authors approximately 18 days after submission; acceptance to publication is undertaken in 6 days (median values for papers published in this journal in 2018). Following Scopus, the 3-year CiteScore tracker is 4.12 in 2017.


Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation.


Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment. Cancers has an impact factor of 6.162

Open Chemistry

Open Chemistry, launched 16 years ago, is a peer-reviewed, open access journal that publishes original research, reviews and short communications in the fields of chemistry in an ongoing way. Our central goal is to provide a hub for researchers working across all subjects to present their discoveries, and to be a forum for the discussion of the important issues in the field.

Pharma Excipients

Pharma-Excipients is an unique information and exchange excipient platform on major topics related to pharmaceutical excipients (inactive ingredients). pharma excipients covers aspects from the excipient manufacturing to regulatory information. It is the largest platform for information and exchange on pharmaceutical excipients.

Copyright Oxford Global Marketing Limited. All rights reserved.